StrokePhase 1NCT04545892
Capsaicin for Cerebral Perfusion Augmentation.
A Phase 1 study testing Capsaicin in people with Stroke, run by Juan Manuel Marquez Romero at 1 site in Mexico.
Trial summary
To determine the safety and effect of crescent doses of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods We performed serial TCD testing in 30 healthy volunteers divided into five equal groups. Capsaicin doses ranged from 33 to 165 μMol. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Stroke
- What is being tested?
- Capsaicin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteMexico
- Study dates
- 1 Dec 2019to 31 Jul 2020
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Those willing to participate with signed the informed consent form (ICF)
- No diagnosis of any chronic or acute disorder
Who cannot join
- Eating or drinking at least one h before the measurements
- Eating spicy food for one day before testing.
- Hypertension
- Smoking
- Any disorder of the oral cavity
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Unidad de Medicina de Alta Especialidad en Torre Médica CMQ
Aguascalientes, Aguascalientes, 20234
About this study
Official title: Dose-Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation. A Pilot Study
To determine the safety and effect of crescent doses of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods We performed serial TCD testing in 30 healthy volunteers divided into five equal groups. Capsaicin doses ranged from 33 to 165 μMol. We recorded peak systolic and end-diastolic velocities in the middle cerebral artery (MCA), arterial pressure, and perceived pungency (PP) in five minutes intervals up to 20 minutes. We then calculated the mean velocity (MV), the pulsatility index (PI), and the CBF index.
Read the detailed description
Subjects We studied 30 healthy volunteers. Call for volunteer flyers were distributed among undergraduate students of the local faculty of medicine. Interested individuals made an appointment to get more information. Those willing to participate signed the informed consent form (ICF) and received instructions to refrain from eating or drinking at least one h before the TCD measurements, and not to eat spicy food for one day before testing. The volunteers were normotensive, not smoking, not taking any medication, and did not have any oral cavity disorder. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate. Therefore, half of the participants in each dose group received stimulation on either left or right side of the palate. Chemical stimuli From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water. The rehydrated filter paper was applied and remained stationary on the subject's hemi palate's posterior surface during TCD measurements. Participants were instructed not to swallow and to avoid touching the paper filter with their tongue for the 20 minutes of the experiment.
TCD testing With a TCD device (Philips Sonos 7500®), we recorded peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the middle cerebral artery (MCA) through the temporal window of the stimulated side. First, we obtained a basal recording and an immediate recording after stimulation, followed by serial recordings every five minutes and up to 20 minutes. At each time point, we also registered: systolic pressure (SP), diastolic pressure (DP), and perceived pungency (PP) on a visual analog scale. TCD markers of cerebral blood flow From the initial measurements we calculated: Mean velocity (MV) = EDV + [(PSVEDV) / 3], pulsatility index (PI) = PSV - EDV / MV, mean arterial pressure (MAP) = ((2 * DP) + SP) / 3 and, the CBF index (CBFi).
, CBFi = (MAP * 10) / 1.47^PI. Statistical analysis Shapiro Wilkins W-Test were performed. Because the data did not follow a normal distribution, the results of the continuous variables are described as median and ranges. The categorical variables are described as tables of absolute and relative frequencies, and the comparisons between the groups of subjects (according to the dose of capsaicin) were carried out with chi-square tests. To compare the variables studied between the groups of subjects (according to the different doses of capsaicin), Mann-Whitney U-Test tests were used. In order to make comparisons of the baseline state with the changes observed in the study variables over time, various Wilcoxon signed-rank tests were performed.The relationship between pungency ratings and MV response was evaluated by Spearman's rho test. The level of statistical significance was set at 0.05.
- Conditions
- Stroke
- Being tested
- Capsaicin
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CapsaicinDrug
Also called 8-Methyl-N-vanillyl-trans-6-nonenamide
One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
| Study group | Role | What they receive |
|---|---|---|
| Capsaicin | Experimental | From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate. Receives: Drug: Capsaicin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean velocity
The Mean velocity in the Middle Cerebral Artery
Measured: 20 minutes
Pulsatility Index
A calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle.
Measured: 20 minutes
Secondary outcomes (2)
Mean arterial pressure (MAP)
The average arterial pressure throughout one cardiac cycle, systole, and diastole.
Measured: 20 minutes
Cerebral Blood Flow index
The result of the following formula: CBFi = (MAP * 10) / 1.47^Pulsatility Index.
Measured: 20 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2020
- Study start1 Dec 2019
- Primary completion31 Jul 2020
- Study completion31 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Juan Manuel Marquez Romero
- Sponsor type
- University, hospital or other
- Collaborators
- Centenario Hospital Miguel Hidalgo, Universidad de Guanajuato
- Responsible party
- Sponsor-investigator, Juan Manuel Marquez Romero, Unidad de Medicina de Alta Especialidad, Torre Medica CMQ
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04545892
- Sponsor's protocol ID
- Cap1
- Status last verified
- Sep 2020
- First submitted
- 4 Sep 2020
- Last updated
- 11 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared with any qualified investigator upon request to the PI after signing a data use agreement.
Publications
Marquez-Romero JM, Huerta-Franco MR, Vargas-Luna M, Madrigal-Gutierrez CA, Esparza-Hernandez JM, Velazquez-Barcena MG. Dose Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation: A Pilot Study. Stroke. 2021 Jul;52(7):2203-2209. doi: 10.1161/STROKEAHA.120.032773. Epub 2021 May 10.
PubMed 33966493
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation. A Pilot Study
- ClinicalTrials.gov ID
- NCT04545892
- Acronym / sponsor ID
- Cap1
- Conditions
- Stroke
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Juan Manuel Marquez RomeroUniversity, hospital or other
- Collaborators
- Centenario Hospital Miguel Hidalgo, Universidad de Guanajuato
- Study start
- 1 Dec 2019 (actual)
- Primary completion
- 31 Jul 2020 (actual)
- Study completion
- 31 Jul 2020 (actual)
- First posted
- 11 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the safety and effect of crescent doses of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods We performed serial TCD testing in 30 healthy volunteers divided into five equal groups. Capsaicin doses ranged from 33 to 165 μMol. We recorded peak systolic and end-diastolic velocities in the middle cerebral artery (MCA), arterial pressure, and perceived pungency (PP) in five minutes intervals up to 20 minutes. We then calculated the mean velocity (MV), the pulsatility index (PI), and the CBF index.
Detailed description
Subjects We studied 30 healthy volunteers. Call for volunteer flyers were distributed among undergraduate students of the local faculty of medicine. Interested individuals made an appointment to get more information. Those willing to participate signed the informed consent form (ICF) and received instructions to refrain from eating or drinking at least one h before the TCD measurements, and not to eat spicy food for one day before testing. The volunteers were normotensive, not smoking, not taking any medication, and did not have any oral cavity disorder. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate. Therefore, half of the participants in each dose group received stimulation on either left or right side of the palate. Chemical stimuli From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water. The rehydrated filter paper was applied and remained stationary on the subject's hemi palate's posterior surface during TCD measurements. Participants were instructed not to swallow and to avoid touching the paper filter with their tongue for the 20 minutes of the experiment.
TCD testing With a TCD device (Philips Sonos 7500®), we recorded peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the middle cerebral artery (MCA) through the temporal window of the stimulated side. First, we obtained a basal recording and an immediate recording after stimulation, followed by serial recordings every five minutes and up to 20 minutes. At each time point, we also registered: systolic pressure (SP), diastolic pressure (DP), and perceived pungency (PP) on a visual analog scale. TCD markers of cerebral blood flow From the initial measurements we calculated: Mean velocity (MV) = EDV + [(PSVEDV) / 3], pulsatility index (PI) = PSV - EDV / MV, mean arterial pressure (MAP) = ((2 * DP) + SP) / 3 and, the CBF index (CBFi).
, CBFi = (MAP * 10) / 1.47^PI. Statistical analysis Shapiro Wilkins W-Test were performed. Because the data did not follow a normal distribution, the results of the continuous variables are described as median and ranges. The categorical variables are described as tables of absolute and relative frequencies, and the comparisons between the groups of subjects (according to the dose of capsaicin) were carried out with chi-square tests. To compare the variables studied between the groups of subjects (according to the different doses of capsaicin), Mann-Whitney U-Test tests were used. In order to make comparisons of the baseline state with the changes observed in the study variables over time, various Wilcoxon signed-rank tests were performed.The relationship between pungency ratings and MV response was evaluated by Spearman's rho test. The level of statistical significance was set at 0.05.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Capsaicin | Experimental | Drug: CapsaicinFrom an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Those willing to participate with signed the informed consent form (ICF)
- No diagnosis of any chronic or acute disorder
Key exclusion criteria (5 listed)
- Eating or drinking at least one h before the measurements
- Eating spicy food for one day before testing.
- Hypertension
- Smoking
- Any disorder of the oral cavity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CapsaicinAlso: 8-Methyl-N-vanillyl-trans-6-nonenamideOne milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water | Drug | Capsaicin |
Primary outcome
Mean velocity
Time frame: 20 minutes
The Mean velocity in the Middle Cerebral Artery
Pulsatility Index
Time frame: 20 minutes
A calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle.
2 secondary outcomes
Mean arterial pressure (MAP)
Time frame: 20 minutes
Cerebral Blood Flow index
Time frame: 20 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2020.
- Derived from this study: PubMed 33966493Marquez-Romero JM, Huerta-Franco MR, Vargas-Luna M, Madrigal-Gutierrez CA, Esparza-Hernandez JM, Velazquez-Barcena MG. Dose Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation: A Pilot Study. Stroke. 2021 Jul;52(7):2203-2209. doi: 10.1161/STROKEAHA.120.032773. Epub 2021 May 10.
- Individual participant dataSharing planned: Yes. Data will be shared with any qualified investigator upon request to the PI after signing a data use agreement.
Related trials for Stroke
Recruiting
Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory
Ischemic Stroke
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Not yet recruitingPhase 4
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Ischemic Stroke
RecruitingObservational study
CoMind Early Feasibility Study
Intracranial Pressure, Intracranial Pressure Changes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Capsaicin in people with Stroke, run by Juan Manuel Marquez Romero at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean velocity (time frame: 20 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04545892, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2020.